AI-Debiased Article
Rewritten from Washington Examiner 1 min read
4 Wire-neutral provisional

✓ No loaded language, vague sourcing, or framing detected.

FDA Approves Marketing of Zyn Nicotine Pouches as Lower Risk than Cigarettes

The FDA has approved Philip Morris International's request to market Zyn nicotine pouches as a lower health risk compared to cigarettes. This decision allows the company to promote the pouches with claims about reduced risks of various health issues, although public health advocates caution that the messaging may lead to misunderstandings regarding the need for complete cessation of cigarette use.

Companies
Philip Morris International Swedish Match USA
People
Bret Koplow

The Food and Drug Administration (FDA) has authorized Philip Morris International to market Zyn nicotine pouches as presenting a lower health risk compared to cigarettes. This decision, announced on June 30, 2026, allows 20 varieties of Zyn to include statements that using Zyn instead of cigarettes reduces the risk of various health issues, including mouth cancer and heart disease. However, the FDA does not classify these products as safe.

The FDA's review indicated that Zyn products expose users to significantly fewer harmful chemicals than traditional cigarettes and may assist some smokers in transitioning away from combustible tobacco. Bret Koplow, acting director of the FDA’s Center for Tobacco Products, emphasized the importance of providing adult consumers with clear, science-based information regarding the relative harms of tobacco products.

Zyn, produced by Swedish Match USA and owned by Philip Morris International, consists of small nicotine-filled pouches that are placed between the lip and gum, and do not contain tobacco leaf. The FDA's decision follows a thorough review process that included input from independent advisers and agency scientists, who generally agreed on the lower health risks associated with these products.

However, public health advocates, including those from the University of California, San Francisco’s Center for Tobacco Control Research and Education, have expressed concerns that the modified risk claim may lead to misunderstandings about the necessity of completely stopping cigarette use. A letter from the center highlighted that the claim could be misinterpreted as FDA approval for cessation, which may not convey the need for complete switching to achieve the stated benefits.

The market for nicotine pouches has seen rapid growth, with Philip Morris reporting nearly 794 million cans of Zyn sold in the United States last year, more than doubling sales from two years prior. Tobacco manufacturers have also sought to expedite the FDA’s authorization process for new nicotine products in response to increasing demand.

Annotating as

No note attached

on this article.

Original vs. Neutral

Original Headline

FDA to allow Zyn nicotine pouches to be marketed as less harmful than cigarettes

Neutral Headline

FDA Approves Marketing of Zyn Nicotine Pouches as Lower Risk than Cigarettes